The AXIS Study: the Efficacy of Acetazolamide for the Treatment of Cystoid Fluid Collections in Retinoschisis

Plain-language summary

This study evaluated the effectiveness of the drug Acetazolamide in treating fluid (cystoid) collections in the retina in people with X-linked retinoschisis. Patients with cystoid fluid collections affecting the central vision (fovea) took part. It was conducted in Phase 2 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 2

Status

Completed

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Intervention

Acetazolamide

Start date

1/20/2023

Estimated completion

9/13/2024

Countries

Netherlands

Related genes

Locations

• Amsterdam, Netherlands

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patients with XLRS with cystoid fluid collections involving the fovea confirmed on SD- OCT
* are willing to undergo ophthalmic examinations at seven separate occasions;
* have no visual dysfunction that is also significantly associated with other ocular diseases besides XLRS (e.g., glaucoma, perforating trauma);
* have no known (non-)ocular disease/disorder which may influence the results of the measurements.

Exclusion Criteria:

* Severe hepatic impairment
* Severe renal insufficiency
* Sodium and Potassium Depletion
* Addison's disease
* Hyperchloremic Acidosis
* Cor pulmonale
* Chronic non-congestive angle-closure glaucoma
* Usage of acetazolamide
* Known allergy or intolerance for ocular anesthetic eye drops oxybuprocaine 0.4% or mydriatics tropicamide 0.5% and/or phenylephrine 5%;